Bob Bradway, Amgen CEO (Alamy Reuters)
February 8, 2022 02:24 PM EST
Pharma

Af­ter Q4 sales sink, Am­gen CEO Bob Brad­way de­tails lofty growth strat­e­gy for 2030: Can he pull it off?

Nicole DeFeudis

Editor

While Am­gen boast­ed a 2% rev­enue boost last year, that growth was large­ly dri­ven by prof­its from the com­pa­ny’s Covid-19 man­u­fac­tur­ing deal with Eli Lil­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

Ex­clu­sive: Can oral an­ti­bod­ies work? A small start­up thinks it has an an­swer

A service from the Financial Times